Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Multiple endocrine neoplasias.

J E Phay1, J F Moley, T C Lairmore

  • 1Department of Surgery, Washington University School of Medicine, St. Louis, Missouri, USA.

Seminars in Surgical Oncology
|May 11, 2000
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Expression of the GLUT1 and GLUT9 facilitative glucose transporters in embryonic chondroblasts and mature chondrocytes in ovine articular cartilage.

Cell biology international·2005
Same author

Endocrine pancreatic tumors.

Scandinavian journal of surgery : SJS : official organ for the Finnish Surgical Society and the Scandinavian Surgical Society·2005
Same author

[Association of deletions of the RET proto-oncogene wtih aggressive course of sporatic C-cell carcinoma].

Langenbecks Archiv fur Chirurgie. Supplement. Kongressband. Deutsche Gesellschaft fur Chirurgie. Kongress·2003
Same author

Surgical treatment of medullary thyroid carcinoma.

Journal of internal medicine·2003
Same author

Molecular characterization and partial cDNA cloning of facilitative glucose transporters expressed in human articular chondrocytes; stimulation of 2-deoxyglucose uptake by IGF-I and elevated MMP-2 secretion by glucose deprivation.

Osteoarthritis and cartilage·2003
Same author

Allelic imbalance of the mutant and wild-type RET allele in MEN 2A-associated medullary thyroid carcinoma.

Oncogene·2001
Same journal

Preoperative chemoradiation for locally advanced rectal cancer: rationale, technique, and results of treatment.

Seminars in surgical oncology·2003
Same journal

Preoperative chemoradiation for locally advanced rectal adenocarcinoma-the University of Florida experience.

Seminars in surgical oncology·2003
Same journal

Postoperative adjuvant therapy for pancreatic cancer.

Seminars in surgical oncology·2003
Same journal

Conformal chemoradiation for primary and metastatic liver malignancies.

Seminars in surgical oncology·2003
Same journal

Gastrectomy, peritonectomy, and perioperative intraperitoneal chemotherapy: the evolution of treatment strategies for advanced gastric cancer.

Seminars in surgical oncology·2003
Same journal

Combined modality therapy in esophageal cancer: the Memorial experience.

Seminars in surgical oncology·2003
See all related articles

Multiple endocrine neoplasia (MEN) syndromes involve tumors in endocrine glands, stemming from the MEN 1 gene or RET proto-oncogene. Genetic testing for MEN 2 revolutionized treatment, enabling early thyroid removal.

Area of Science:

  • Endocrinology
  • Genetics
  • Oncology

Background:

  • Multiple endocrine neoplasia (MEN) syndromes comprise MEN 1 and MEN 2, affecting various endocrine glands.
  • MEN 1 is linked to the MEN 1 tumor suppressor gene, causing parathyroid hyperplasia, pancreaticoduodenal neuroendocrine tumors (PNTs), and pituitary adenomas.
  • MEN 2 syndromes (MEN 2A, MEN 2B, familial non-MEN medullary thyroid carcinoma) are associated with the RET proto-oncogene and characterized by medullary thyroid cancer.

Purpose of the Study:

  • To summarize the genetic basis and clinical manifestations of MEN 1 and MEN 2 syndromes.
  • To highlight the role of genetic testing in managing MEN 2.
  • To discuss current treatment modalities for MEN 1.

Main Methods:

  • Review of existing literature on MEN 1 and MEN 2 genetics and clinical features.

Related Experiment Videos

  • Analysis of treatment strategies, focusing on surgical interventions for MEN 1 and genetic testing for MEN 2.

    • Main Results:

    • MEN 1 involves parathyroid, pancreas, and pituitary tumors, with surgery as the primary treatment, though timing and extent remain debated for PNTs.
    • MEN 2 syndromes consistently feature medullary thyroid cancer, with variable presence of hyperparathyroidism, pheochromocytomas, and other features.
    • RET gene mutation testing has transformed MEN 2 management, allowing prophylactic thyroidectomy before disease onset.

    Conclusions:

    • MEN syndromes arise from specific genetic mutations (MEN 1 gene, RET proto-oncogene).
    • Genetic testing is crucial for early diagnosis and intervention in MEN 2, significantly improving patient outcomes.
    • Further research is needed to optimize surgical timing and extent for PNTs in MEN 1.